EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

The Global Antifungal Susceptibility Epidemiology of Trichophyton indotineae Indicating Voriconazole as an Alternative Therapy for Recalcitrant Dermatophytosis

Ge Song, Wenting Xie, Xiaodong She, Weida Liu, Xiaofang Li iD, Guanzhao Liang iD

Mycoses · 2026-06 · 69 (6)

DOI: 10.1111/myc.70195 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Mycoses, online erschienen am 05.06.2026. Verfasst von Ge Song und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Antifungal Agents, Voriconazole, Trichophyton, Tinea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, CAMS Innovation Fund for Medical Sciences (CIFMS), Natural Science Foundation Program of Beijing, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The emergence of Trichophyton indotineae as a multidrug‐resistant dermatophyte has challenged conventional therapeutic approaches for dermatophytosis, leading to a significant therapeutic dilemma. The absence of formal epidemiological cutoff values (ECVs) under the Clinical and Laboratory Standards Institute (CLSI) framework has led to inconsistent interpretation of antifungal susceptibility testing (AFST) data, highlighting the urgent need for standardised susceptibility interpretation criteria and effective therapeutic strategies.

Objectives

This study aimed to (1) establish CLSI‐based estimated tentative ECVs (ET‐ECVs) to facilitate reliable minimum inhibitory concentration (MIC) interpretation; (2) analyse resistance rates of T. indotineae to terbinafine, itraconazole and voriconazole using a large‐scale global dataset and (3) explore and identify effective therapeutic options following first‐line treatment failure.

Methods

This systematic review compiled global susceptibility data for T. indotineae through comprehensive literature searches, including only studies that performed CLSI‐ or European Committee on Antimicrobial Susceptibility Testing (EUCAST)‐standardised AFST. Furthermore, the clinical efficacy of voriconazole was specifically evaluated by summarising and analysing reported treatment cases.

Results

A total of 67 studies from 14 countries, comprising 981 isolates, were included. The proposed CLSI ET‐ECVs for terbinafine, itraconazole and voriconazole were 0.125, 0.25 and 1 mg/L, respectively, showing full alignment with EUCAST tentative epidemiological cutoff values (TECOFFs). Integrated resistance rates were 77.6% for terbinafine, 17.0% for itraconazole and 1.4% for voriconazole. Cross‐resistance analysis revealed that terbinafine resistance predominated, with 14.3% of isolates co‐resistant to itraconazole. In vitro susceptibility data demonstrated high activity of voriconazole and clinical case summaries further confirmed its favourable therapeutic efficacy, with complete remission reported in all evaluated cases.

Conclusion

This study defined the CLSI ET‐ECVs for interpreting T. indotineae MICs, highlighted the resistance burden to first‐line agents and provided in vitro evidence supporting further evaluation of voriconazole as a potential effective alternative therapy. These findings may provide critical warnings regarding the high‐resistance landscape and help guide antifungal susceptibility interpretation for this emerging multidrug‐resistant pathogen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsVoriconazoleTrichophytonTineaHumansMicrobial Sensitivity TestsDrug Resistance, FungalItraconazoleTerbinafine

Stichwörter der Autor:innen

Trichophyton indotineaeCLSIEUCASTantifungal drug resistancevoriconazole

Substanzen

Antifungal AgentsVoriconazoleItraconazoleTerbinafine

Autor:innen und Institutionen

  • Department of Dermatology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Department of Medical Mycology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.
  • Jiangsu Provincial Key Laboratory of Dermatology, Nanjing, China.
  • CAMS Collection Centre of Pathogen Microorganisms-D (CAMS-CCPM-D), Nanjing, China.

ORCID-Profile: Xiaofang Li, Guanzhao Liang

Förderung

  • National Key Research and Development Program of China
  • CAMS Innovation Fund for Medical Sciences (CIFMS)
  • Natural Science Foundation Program of Beijing, China
  • Jiangsu Provincial Medical Key Laboratory, Jiangsu Province Capability Improvement Project through Science, Technology and Education

Zitieren

APA

Song, G., Xie, W., She, X., Liu, W., Li, X., & Liang, G. (2026). The Global Antifungal Susceptibility Epidemiology of Trichophyton indotineae Indicating Voriconazole as an Alternative Therapy for Recalcitrant Dermatophytosis. Mycoses, 69(6). https://doi.org/10.1111/myc.70195

Vancouver

Song G, Xie W, She X, Liu W, Li X, Liang G. The Global Antifungal Susceptibility Epidemiology of Trichophyton indotineae Indicating Voriconazole as an Alternative Therapy for Recalcitrant Dermatophytosis. Mycoses. 2026;69(6). doi:10.1111/myc.70195

BibTeX
@article{Song2026,
  author = {Song, Ge and Xie, Wenting and She, Xiaodong and Liu, Weida and Li, Xiaofang and Liang, Guanzhao},
  title = {The Global Antifungal Susceptibility Epidemiology of Trichophyton indotineae Indicating Voriconazole as an Alternative Therapy for Recalcitrant Dermatophytosis},
  journal = {Mycoses},
  year = {2026},
  volume = {69},
  number = {6},
  doi = {10.1111/myc.70195}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche